Anika Therapeutics Inc. Selling, General and Administrative Expense of Revenue

Selling, General and Administrative Expense of Revenue of ANIK for past 10 years: annual, quarterly and twelve month trailing (TTM) including Selling, General and Administrative Expense of Revenue growth rates and interactive chart.


Highlights and Quick Summary

  • Selling, General and Administrative Expense of Revenue for the quarter ending September 29, 2021 was 44.26% (a -6.15% decrease compared to previous quarter)
  • Year-over-year quarterly Selling, General and Administrative Expense of Revenue decreased by -4.69%
  • Annual Selling, General and Administrative Expense of Revenue for 2020 was 42.11% (a 39.67% increase from previous year)
  • Annual Selling, General and Administrative Expense of Revenue for 2019 was 30.15% (a -7.32% decrease from previous year)
  • Annual Selling, General and Administrative Expense of Revenue for 2018 was 32.53% (a 71.3% increase from previous year)
  • Twelve month Selling, General and Administrative Expense of Revenue ending September 29, 2021 was 47.59% (a -3.17% decrease compared to previous quarter)
  • Twelve month trailing Selling, General and Administrative Expense of Revenue increased by 3.37% year-over-year
Trailing Selling, General and Administrative Expense of Revenue for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
47.59% 49.15% 49.33% 46.04%
Visit stockrow.com/ANIK for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Selling, General and Administrative Expense of Revenue of Anika Therapeutics Inc.

Most recent Selling, General and Administrative Expense of Revenueof ANIK including historical data for past 10 years.

Interactive Chart of Selling, General and Administrative Expense of Revenue of Anika Therapeutics Inc.

Anika Therapeutics Inc. Selling, General and Administrative Expense of Revenue for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 44.26% 47.16% 53.0%
2020 46.44% 50.18% 47.43% 40.77% 42.11%
2019 41.1% 25.39% 24.66% 31.03% 30.15%
2018 22.74% 21.28% 21.01% 75.67% 32.53%
2017 22.72% 17.74% 14.86% 21.67% 18.99%
2016 19.1% 16.6% 16.01% 17.91% 17.42%
2015 14.64% 13.97% 14.79% 23.23% 15.94%
2014 15.79% 18.34% 14.71% 10.26% 14.28%
2013 11.29% 17.96% 16.33% 25.89% 17.23%
2012 16.22% 24.39% 20.94% 23.33% 20.64%
2011 26.4% 25.53% 26.23% 34.45% 27.57%
2010 28.21% 31.17%

Business Profile of Anika Therapeutics Inc.

Sector: Healthcare
Industry: Medical Devices
Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses. It also offers joint preservation and restoration products comprising preserving joint technologies, such as partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions caused by trauma, injury, and arthritic disease; soft tissue repair solutions used by surgeons to repair and reconstruct damaged ligaments and tendons resulting from sports injuries, trauma, and disease; Tactoset, an HA-enhanced injectable bone repair therapy to treat insufficiency fractures; and Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery. In addition, the company provides Hyalobarrier, an anti-adhesion barrier for use after abdomino-pelvic surgeries; Hyalomatrix for the treatment of complex wounds, such as burns and ulcers; products for the treatment of ears, nose, and throat disorder; and ophthalmic products, including injectables, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, consisting of cataract extraction and intraocular lens implantation. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.